Showing posts with label genetic mutation. Show all posts
Showing posts with label genetic mutation. Show all posts

01 September 2009

Say goodbye to inheritable diseases


The recent successful birth of twin healthy monkeys through a new gene therapy known as spindle transfer has provided hope in preventing a chain of inherited diseases which are passed from mothers to their offspring through mutated DNA in the mother’s cell mitochondria (Paddock 2009). Although uncommonly known, the mitochondria like the cell nucleus contain their own genome which is derived predominantly from the egg. Therefore, with each individual cell harboring numerous mitochondria, mutations in this DNA can occur at higher rate than nuclear DNA, resulting in 150 known diseases such as Parkinson’s disease which can be passed on to the embryo (Tachibana et al. 2009).

The fertility method, spindle transfer prevents this inheritance of mutated mitochondrial DNA through the transfer of intact spindle-chromosomal complexes [of the metaphase II stage] into a healthy donor egg containing only of healthy mitochondrial DNA. In this case, the researchers of Oregon Heath and Science University’s Oregon National Primate Research center then tested the result of this experiment in monkeys. The resumption of meiosis in the new egg was first activated through electrofusion pulse before it was fertilized by the addition of male sperm (Tachibana et al. 2009). When it was developed into an embryo, it was then implanted in female surrogate monkeys where twin monkeys, “Mito” and “Tracker” were born (Paddock 2009).

At first it was feared by these US researchers that significant mitochondrial DNA would still be able to crossover when transferred to the donor egg, however previous investigations into the distribution of mitochondria in mature Metaphase II stage oocytes has shown that spindles and metaphase chromosomes were devoid of mitochondria. Instead, the mitochondria were found to be safely suspended uniformly throughout the cytoplasm. The other obstacle involving the safe isolation of spindle-chromosomal complex was also found to be negligible through the help of a new non-invasive microscopy which avoids ultraviolet exposure and Hoechst staining damage on cell replication (Tachibana et al. 2009).

Despite the fact that there are some subtle differences between monkeys and humans in general, it is believed that this successful experiment would go forward as a theoretical approach in assisting the building of healthy future generations of children who may have a family history of diseases. Dr Shoukhrat Mitalipov, one of the researchers, claims, “We believe that with the proper governmental approvals, our work can rapidly be translated into clinical trials for humans and eventually approved therapies.” (Paddock 2009).

Ivy Tseng 42034153

For article by Catherine Paddock, PhD 28 August 2009:

http://www.medicalnewstoday.com/articles/162266.php

For original research paper, “Mitochondrial gene replacement in primate offspring and embryonic stem cells” by Masahito Tachibana, Michelle Sparman, Hathaitip Sritanaudomchai, Hong Ma, Lisa Clepper, Joy Woodward, Ying Li, Cathy Ramsey, Olena Kolotushkina and Shoukhrat Mitalipov 26 August 2009:

http://www.nature.com.ezproxy.library.uq.edu.au/nature/journal/vaop/ncurrent/full/nature08368.html

For supplementary information:

http://www.nature.com.eqproxy.library.uq.edu.au/nature/journal/vaop/ncurrent/suppinfo/nature08368.html

19 April 2009

Risk of Stroke Increased by Gene Mutation

A regular gene mutation that affects certain people in their iron metabolism is almost three times more likely to induce stroke, a new study reports. Researchers say believe that this discovery will aid doctors in recognising and diagnosing patients who are most prone to stroke, allowing them to take precautionary procedures.

According to the study, nearly one in four Europeans carry one defective copy of this gene, called HFE. Borge Nordestgaard at Herlev University Hospital in Copenhagen, Denmark, elucidates that a minute alteration in the HFE gene, described as the H63D defect, appears to result in an excessive iron uptake into the cells from blood. This iron overload typically goes unobserved and some people may develop liver cirrhosis* late in life as a consequence.

Nordestgaard and colleagues collected DNA samples from 9000 people in Denmark and observed their health over the course of 24 years in an attempt to properly investigate whether the nervous system was being affected by this gene. Within the allocated time approximately 400 participants suffered an ischemic** stroke (a sudden loss of blood supply to a region of the brain.)

Of the 156 subjects with two copies of the defective HFE gene, 10 percent died from this type of stroke during the study. Only 4% of people with one or no mutated versions of HFE died from stroke. After adjusting for potential experimental factors such as age, gender and cholesterol levels, researchers determined that people with two mutated HFE genes had a 180% elevated risk of stroke than those without mutations in the gene.

* Cirrhosis is a liver disease in which scarring and damage of the liver cells occur along with an interruption of blood flow through the liver.

** Ischemic (from Ischemia) is the restriction of blood flow.
By Ronik Ghosh 41616794

References

Khamsi R, 2007. Common gene mutation linked to tripled stroke risk. Viewed 19 April 2009,
http://www.newscientist.com/article/dn11469-common-gene-mutation-linked-to-tripled-stroke-risk-.html

University of Washington, 2009. CT Scan of Brain with Ischemic Tumor. Viewed 19 April 2009,
http://uwmedicine.washington.edu/NR/rdonlyres/BC938DFF-8E45-4E14-BC92-3D5E2C1C9DDA/0/CTIschemicNormal.jpg


02 April 2009

Link Between Genetic Mutation and Neurodegenerative Diseases

A recent review article in Nature Neuroscience, revealed that stress on the endoplasmic reticulum (ER), caused by an incorrect DNA sequence in myelinating nerve cells, is a key factor in the development of various neural demyelinating disorders such as Pelizaeus-Merzbacher Disease and Multiple Sclerosis.
Myelin is a unique lipid sheath that wraps around the axons of neurons in the Central Nervous system (CNS) and Peripheral Nervous System (PNS). They are essential for the fast conduction of electrical impulses (action potential) as well as the maintenance of the axonal integrity. In the CNS, the proteolipid protein (PLP) plays a major factor in the compaction and wrapping of the myelin secreted by brain cells called oligodendrocytes. Mutations in the PLP gene (PLP1) has been shown to synthesise non-functional proteins which are unable to be folded correctly within the oligodendrocyte’s ER. These mutant proteins then accumulate in the ER, disturbing the cell’s endoplasmic reticulum ultrastructure and place increased pressure on the ER. The cell responds to this with the ‘unfolded protein response’ (UPR) either in an adaptive or apoptosis (suicidal) pathway.

If the adaptive pathway is undertaken, the cell uses methods such as expanding the ER or transcribing cytoprotective genes to try and cope. Despite these measures, the myelin sheath will be structurally defective; and whilst the cell may live, its messaging transmission capabilities would be hindered. If the UPR deems the cells as ‘too-stressed-out’ it will initiate cell apoptosis. While the exact methods on how the UPR chooses whether to initiate apoptosis or adaption is unclear, it is generally postulated that the outcome of ER stress is related to the developmental status of the cell.

From the catching of a ball and speech, to the typing at a keyboard, all these are made possible by the firing of neurons and their protective myelin sheaths. Without the myelin, the electrical impulses are chopped and slow resulting in motor and neural difficulties. Without PLP, myelin would not be able to be compacted and wrapped correctly and excess junk PLP can cause cell death from ER stress. Furthermore, as this misfolding has been shown to be a genetic mutation in PLP1, and this has implications in the heritability of neurodegenerative disorders but it also opens some avenues for the testing of these diseases. Though considerable progress has been made in the understanding of the pathways a cell undertakes in relation to ER stress, recent studies have begun to suggest that the manipulation of these signalling pathways has a potential to be therapeutic.

...and so as an exciting sidenote, groundbreaking research into the PLP 1 gene sequence and its role in relation to the neurodegenerative disease, Multiple Sclerosis (MS) is actually currently being undertaken here, in Queensland, at the University of Queensland’s Centre for Clinical Research (UQCCR)by Dr Judith Greer’s Group. They hope to link the PLP1 gene mutation with MS and possibly also develop a drug to reduce MS's relapse attack severity. Though largely untouched by the Australian research community, the PLP gene and protein will most certainly play a key role in the research of certain neurodegenerative diseases, such as MS, now and into the future.

Article: Lin, W., & Popko, B. (2009). Endoplasmic reticulum stress in disorders of myelinating cells. Nature Neuro. , 379-383.
(http://www.nature.com/neuro/journal/v12/n4/abs/nn.2273.html) [Abstract only]
University of Queensland’s Centre for Clinical Research
http://www.uqccr.uq.edu.au/

Dr Judith Greer’s Group
http://www.uqccr.uq.edu.au/about-uqccr/staff/staff-profiles/dr-judith-greer.aspx#description

By Antony Ji (42004192)

29 March 2009

Why Nicotine Works in Brain Receptors, But Not Muscle Receptors



(Original article: “Insight Into the Way Nicotine Works in the Brain.”, ScienceDaily, March 29, 2009)


Nicotine binds to brain receptors, and as is fairly common knowledge, is an addictive substance.
Nicotine binds to a type of acetylcholine receptor in neurones (brain cells). This same type of acetylcholine receptor is also prevalent in muscle cells. Nicotine binds to the neurones’ acetylcholine receptors. If it were to bind to the muscle cells’ equivalent, the smoker, in this scenario, would be paralyse or die from violent muscular contractions.
Research from the California Institute of Technology, led by Professor Dennis Dougherty, has indicated that the reason smokers don’t perish in violent fits of muscular spasm upon taking a drag, is of a genetic nature; a genetic mutation is responsible.
Even though the acetylcholine receptors in brain and muscle cells are essentially the same, their structures are slightly different. Chemical interactions are important in a receptor’s shape and how a chemical binds to it. A cation π interaction explains how acetylcholine bind to acetylcholine receptors in muscle cells.
In muscle cells, nicotine is not capable of doing so. However, in the brain’s neurones’ acetylcholine receptors, nicotine can bind. Nicotine, in brain cells, can make strong cation π interactions and strong hydrogen bonds.
This is all because of a mutation in the receptors. The mutation in the brain cells’ receptors, allows nicotine to “fit” closely with tryptophan, to all the cation π interaction. Nicotine and the receptors’ tryptophan can be closer in the brain cells than in muscle cells.
Dougherty concludes that this is the reason for nicotine’s addictiveness.
So, negatively, this genetic mutation creates addicts out of some persons who indulge in cigarettes, but on a positive note, saves those who do so from violent, and potentially lethal muscular contractions.


By:
420 972 60



References:
California Institute of Technology (2009, March 29). Insight Into The Way Nicotine Works In The Brain. ScienceDaily. Retrieved March 29, 2009, from http://www.sciencedaily.com¬ /releases/2009/03/090323161121.htm [Accessed 29th March, 2009]

Journal reference:
1. Xiu et al. Nicotine binding to brain receptors requires a strong cation–π interaction. Nature, March 26, 2009; DOI: 10.1038/nature07768 Adapted from materials provided by California Institute of Technology, via EurekAlert!, a service of AAAS.

26 March 2009

Genetic research gives healthy new prospects for Tobacco

Tobacco isn't the first plant many people think of when it comes to good health. However, advances in plant genetic engineering have given new hope and prospects for the future of this plant in area of human health.

Led by Professor Mario Pezzoti at the University of Verona, a large team scientists from many European institutions have come together to explore the potential of transgenic tobacco to produce active biopharmaceuticals. Professor Pezotti and his team set out to create bioactive Interleukin-10 (IL-10), a powerful anti-inflammatory cytokine, in transgenic tobacco tissues.

Two different sources of the IL-10 gene were investigated, one viral and one from a mouse, as well as different targeting compartments within each cell. the researchers found that the transgenic plants were able to produce both types of IL-10 equally, and at a high enough level that the leaves themselves might be usable without a lengthy extraction and purification process to access the desired protein. the next step will be to feed these plant tissues to mice with auto-immune disorders to see if the IL-10 proteins are useful in this form.

With this advance in using transgenic tobacco to produce active forms of biopharmacueticals, there is hope that plants may become biofactories in the future, creating many types of useful proteins related to health applications for a fraction of the cost of modern factories.

Original Article: http://www.sciencedaily.com/releases/2009/03/090318211236.htm

24 March 2009

Scientists See a Cure for Blindness



Recent talk in the scientific world has questioned the relationship between glaucoma, a disease that causes cells in the optic nerve to die, and the gene WDR36, a cell associated with cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. Put simply, researchers at the University of Alberta may be one step closer to finding a cure for glaucoma, which is the leading cause of blindness. While the disease is usually related to aging, it can also appear in children as young as three years old.

Despite previous researchers having suspected this link, it has been unknown as to why some people with mutations of the gene get the disease and others don’t, until now. Dr. Michael Walter chair of the department of medical genetics in the faculty of medicine and dentistry is foremost in this revolutionary case.
"We investigated what WDR36 does and what we found was the mutations of this gene only have a deleterious effect when mutations of other genes were also present," Walter clarified.
"What this means is that you need to have several different mutations simultaneously to get glaucoma. Ultimately, we hope by understanding this process, we will be able to certainly diagnose and treat patients." Walter continues that "When these genes are mutated, we get a new process which we didn't know was involved in glaucoma. So by understanding this we can try to tease apart some of the basic causes of the disease."

Ultimately, this research has also opened the door to other genetic factors that could be involved with glaucoma that have not previously been considered.

Currently there's 65 million people worldwide who are suffering from this disease, and Walter maintains that his research will cure 67% of this populace, with the goal of curing all affected.

The research team's results will be published in the April 1 edition of the Human Molecular Genetics journal.

42028639

Pictures from:

22 March 2009

The Blue Eyed Man


According to a danish researcher, blue eyes are the result of a single mutation that occured 10,000 years ago.


Hans Eiberg published his finding in the Journal Human Ginetics based on a mutation that links all people with blue eyes to a single mutation that occured 10 milleniums ago.



In 1996 Eidberg discovered the OCA2 gene which is a defining figure in eye colour, the new discovery of the blue eyed gene was found to be a mutation that works directly at stopping to a certain extent the OAC2 genes production of melanin in the eye. If full shutdown of melanin production occured albinoism would provale but in the case of the blue-eyed mutation the melanin is restricted, resulting the brown colouring to be diluted and becoming a blue iris. Melanin is the pigment that gives colour to hair and eyes.


"Eiberg started his search for the elusive mutation close to home. Using the Copenhagen Family Bank, a massive genetic database with detailed information on over 6,000 Danes, Eiberg found a family with three generations of blue-eyes. Looking at DNA from their blood, Eiberg homed in on a single, tiny blip in the genetic code. "All of the family had the same mutation," he said.


To make sure the Danish family wasn't a fluke, Eiberg tested hundreds more samples, including people from Turkey with dark hair, light skin and blue eyes and Jordanians with dark hair, dark skin and blue eyes. They all had the same mutation as the Danes. "I have analyzed 800 samples," Eiberg says. "Out of the 800, 799 eyes are the same."."


The mutation seen throughout all the blue-eyed people is 'extremely specific', as all the people in the study had the same exact variation which gave rise to Eidbergs idea of a single Ancestor that lived between 6,000 to 10,000 years ago.


Unfortunatley for the blue-eyed people in the world there are no advantages from the mutation apart from the change in eye colour which some scientist argue is an advantage in the world of attraction within certain populations.


by Sam W 4205706





15 March 2009

APP Genes Unique Part in Hereditary Alzheimer’s


Alzheimer's is a progressive, terminal brain disease and is the leading cause of dementia. Scientists at the “Carlo Besta" National Neurological Institute in Milan, Italy have discovered a gene mutation that seems to give protection when inherited from only one parent but causes Alzheimer’s when two copies are inherited. Fabrizio Tagliavini, who along with his colleagues, discovered this mutation hope that this research will lead to the development of new drug therapies that can be used to treat both genetic and sporadic forms of the disease.

The gene mutation found occurs in APP, which makes a protein known as A-beta, is often linked to familial cases of Alzheimer’s. Although only a small proportion of the millions Alzheimer’s cases are linked to single, inherited mutations, this particular mutation is unique in that it needs to be inherited from both parents to cause the disease. Most mutations already identified are dominant and require only one copy to produce the disease.

The mutation was discovered in a patient with signs of early onset Alzheimer’s, but no mutations in other genes associated with the inheritable form of the disease. For further research, cells were taken from a 44-year old man with early onset Alzheimer’s that had two copies of the APP mutation. It was found that his A-beta proteins developed clumps more often then cells from people with normal APP gene. One theory for the cause of Alzheimer’s is linked to the development of such clumps.

Relatives of the early onset Alzheimer’s patient with only one copy of the mutant APP gene did not show any symptoms of the disease, including an 88-year old aunt. This was backed up by the observation that when normal and mutant forms of A-beta were mixed together, there were even less clumps than with the normal protein alone. Indicating that inheritance of only one mutant allele of APP may protect a person from Alzheimer’s disease.

Tugliavini and his colleagues hope the creation of a synthetic protein could be used to recreate the mixture of proteins that reduces clumping in patients with two copies of the mutant gene. In fact his team has found a mutant protein that reduces clumping of the proteins. It is only six units long which hopefully increase the chances of successful travel through out the body.

Even if a drug is not developed the APP mutation discovery will change how scientists view the genetics of Alzheimer’s.


Articles:
http://www.newscientist.com/article/dn16750-paradoxical-gene-causes-and-protects-against-alzheimers.html
http://www.sciencedaily.com/releases/2009/03/090312140846.htm
http://www.sciencemag.org.ezproxy.library.uq.edu.au/cgi/content/full/sci;323/5920/1473?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=tagliavini&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

Other Sources:
http://en.wikipedia.org/wiki/Alzheimer's_disease
http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp